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We conducted a multicenter clinical evaluation of the second versions of the manual AMPLICOR and the
semiautomated COBAS AMPLICOR tests for hepatitis C virus (HCV) RNA (Roche Molecular Systems, Inc.,
Pleasanton, Calif.). The performance characteristics of these HCV RNA tests for diagnosis of active viral
infection were determined by comparison to anti-HCV serological test results, alanine aminotransferase levels,
and liver biopsy histology results. A total of 878 patients with clinical or biochemical evidence of liver disease
were enrolled at four hepatology clinics. A total of 1,089 specimens (901 serum and 188 plasma) were tested
with the AMPLICOR test. Sensitivity compared to serology was 93.1% for serum and 90.6% for plasma. The
specificity was 97% for serum and 93.1% for plasma. A total of 1,084 specimens (896 serum and 188 plasma)
were tested with the COBAS test. Sensitivities for serum and plasma were the same as with the AMPLICOR
test. The specificity was 97.8% for serum and 96.6% for plasma. Of the 69 specimens with false-positive and
false-negative AMPLICOR test results relative to those of serology, alternative primer set (APS) reverse
transcription (RT)-PCR analysis showed that the AMPLICOR test provided the correct result relative to the
specimens containing HCV RNA in 64 (92.7%) specimens. Similarly, 66 of 67 (98.5%) false-positive and
false-negative COBAS test results were determined to be correct by APS RT-PCR analysis. There were no
substantive differences in clinical performances between study sites, patient groups, specimen types, storage
conditions (20 to 80°C versus 2 to 8°C), or anticoagulants (EDTA versus acid citrate dextrose) for either
test. Both tests showed >99% reproducibility within runs, within sites, and overall. We conclude that these tests
can reliably detect the presence of HCV RNA, as evidence of active infection, in patients with clinical or
biochemical evidence of liver disease.
Detection of hepatitis C virus (HCV) RNA in serum or
plasma by nucleic acid amplification methods is important in
confirming the diagnosis of hepatitis C, distinguishing active
from resolved infection, and assessing the response to therapy.
Many different in-house and commercially developed assays,
based on a variety of nucleic acid amplification strategies, have
been described. Nucleic acid amplification assays are part of
the algorithms for diagnosis of hepatitis C proposed by the
National Institutes of Health (15), the Centers for Disease
Control and Prevention (3), the European Association for the
Study of the Liver (7), and the National Academy of Clinical
Biochemistry (6).
Assays for detection of HCV RNA based on reverse tran-
scription (RT)-PCR are commonly used in clinical practice.
Clinical laboratories participating in the College of American
Pathologists nucleic acid amplification proficiency-testing pro-
gram use commercially developed assays almost exclusively. In
a recent survey of participants in this program (CAP 1999
ID-C), the majority (71%) performed RT-PCR with AMPLI-
COR HCV kits (Roche Molecular Systems, Pleasanton, Cal-
if.).
The AMPLICOR HCV tests have been developed in a man-
ual, microwell plate format and an automated format that uses
the COBAS AMPLICOR analyzer. The first generations of
both the manual and automated tests were recently modified to
improve sensitivity and reliability. The modifications include a
10-fold increase in effective sample volume, an internal control
molecule that is added to the specimen prior to nucleic acid
extraction, and addition of a cosolvent to the reaction mixture
to eliminate secondary structure in the target RNA.
Despite the widespread use of the second-generation AM-
PLICOR HCV tests in clinical laboratories, there is only a
single published clinical evaluation (5). In this study, 187 clin-
ical specimens and dilution panels of different HCV genotypes
were tested with the first and second versions of the COBAS
AMPLICOR HCV test. The second version of the test was
found to have greater sensitivity and less genotype bias than
the first version. In a recent study of the analytical performance
characteristics of the second-generation AMPLICOR tests, the
limit of detection was found to be 50 IU of HCV genotype 1
RNA/ml and all genotypes were amplified with similar effi-
ciency (13).
Here we report the results of a multicenter clinical evalua-
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tion of the second versions of both the manual AMPLICOR
and the semiautomated COBAS AMPLICOR tests for HCV
RNA. These tests were recently granted marketing approval by
the U.S. Food and Drug Administration to directly detect the
presence of HCV in the blood. The results of these qualitative
HCV RNA tests were evaluated against anti-HCV serology
results, alanine aminotransferase (ALT) levels, and liver bi-
opsy histology results. The objectives of this study were to
determine the reliability and reproducibility, define the perfor-
mance characteristics, and evaluate the clinical utility of these
tests for patients presenting to hepatology clinics with bio-
chemical or clinical evidence of liver disease.
MATERIALS AND METHODS
Patients. A total of 878 patients were enrolled in the study at the four sites, 137
at Emory University (EU), 344 at Virginia Commonwealth University (VCU),
232 at University of Miami (UM), and 165 at University of Washington (UW).
All patients included in the study presented to hepatology clinics with biochem-
ical or clinical evidence of liver disease, had not received HCV therapy for at
least 6 months prior to enrollment, and had given written informed consent to
participate in the study. The appropriate review committee at each study site
approved the study protocol. A case report form was used to record patient
demographic information, the reason for clinic visit, clinical diagnosis, prior
HCV therapy (if previously treated), and liver biopsy results (if performed). In
cases where liver biopsy was performed prior to enrollment, copies of the his-
tology reports were obtained. The intervals between biopsy and collection of the
serum or plasma for HCV RNA testing varied, so histological findings may not
represent disease activity at the time the specimens were collected. The popu-
lations of patients for whom the AMPLICOR and COBAS AMPLICOR tests
were evaluated differed by only four patients. The demographic information and
clinical history for all of the study patients are summarized in Table 1.
The performance of the HCV RNA testing relative to that of serology testing
was evaluated in all patients and, separately, in three distinct patient groups by
disease state. The diagnosis group included patients who had never been treated
for HCV infection and who had not undergone liver transplantation. These
patients were referred to the clinics for evaluation of HCV infection or other
liver diseases. The previously treated group included patients who had received
antiviral therapy more than 6 months prior to enrollment in the study. Patients
who had undergone liver transplantation prior to enrollment were included in
the posttransplant group. ALT levels were defined as normal or elevated based
on the normal ranges used at the testing sites. Histology reports on liver biopsies
were categorized as having evidence of hepatitis or not having evidence of
hepatitis. Histological features of hepatitis included inflammation and necrosis
typical of hepatitis, and in many cases there were fibrosis and cirrhosis. Hepatitis
cases included viral, autoimmune, and nonalcoholic steatohepatitis.
Specimens. Both serum and plasma specimens were collected for HCV RNA
testing. Blood for serum specimens was collected in VACUTAINER serum
separator tubes (Becton Dickinson, Franklin Lakes, N.J.) and for plasma spec-
imens in either EDTA- or ACD-containing tubes (Becton-Dickinson). Whole
blood was stored at 2 to 25°C for up to 6 h prior to separation into either serum
or plasma. Each serum or plasma specimen was divided into a minimum of six,
220-l single use aliquots. A number of patients had specimens prepared as both
serum and plasma and had serum specimens stored both refrigerated and frozen
prior to testing (Table 2). The refrigerated specimens were tested within 72 h of
specimen collection. Specimens for the reference tests were collected, trans-
ported, and processed according to the standard operating procedures at the
study sites.
Reference methods. Enzyme-linked immunoassays (EIA) for HCV antibodies
were performed at each study site according to the manufacturers’ instructions.
A second-generation test (Abbott, Abbott Park, Ill.) was used at three sites (EU,
VCU, and UW), and a third-generation test (Ortho, Raritan, N.J.) was used at
the remaining site (UM). A second-generation recombinant immunoblot assay
(RIBA) (Chiron, Emeryville, Calif.) was performed on each EIA-reactive spec-
imen according to the manufacturer’s instructions. ALT levels were determined
at each site by standard methods.
Alternative primer set RT-PCR. Nested RT-PCR testing using three alterna-
tive primer sets (APS) derived from the 5 untranslated region (UTR), core, and
envelope 1 regions of the HCV viral genome was performed at UW on those
specimens identified as discrepant at each site. HCV RNA was extracted from
patients’ specimens using Qiaprep viral RNA columns (Qiagen, Valencia, Calif.).
Complementary DNA was synthesized using random hexamers and Moloney
murine leukemia virus reverse transcriptase. The oligonucleotide primer se-
quences and methods for cDNA amplification and amplicon detection have been
previously described (1, 2, 10, 11, 17).
AMPLICOR HCV Test v2.0. The AMPLICOR HCV Test version 2.0 (v2.0) is
an RT-PCR in a manual, microwell format that amplifies a 244-nucleotide
segment of the 5 UTR of the HCV genome. The test was performed at all sites
according to the manufacturer’s instructions as previously described (13). HCV
RNA optical density (OD) values were interpreted as follows: 0.3, negative;
0.3 and 1.0, equivocal; and 1.0, positive. An OD value of 0.3 was used as the
cutoff for the internal control (IC) RNA. Any specimens with OD values of 0.3
for both HCV and IC wells were considered potentially inhibitory (PI).
COBAS AMPLICOR HCV Test v2.0. The COBAS AMPLICOR HCV Test
v2.0 was performed at all sites according to the manufacturer’s instructions as
previously described (13). The COBAS AMPLICOR analyzer combines four
instruments (thermal cycler, incubator, wash station, and photometer) into one
system. Specimen and IC control preparation, RT, and target and IC amplifica-
tion processes were essentially the same as with the manual AMPLICOR test.
TABLE 1. Summary of patient information
Parameter Category Value
Age Mean (SD) 46.2 (10.8)
Range 10–81
Sex [no. (%)] Males 478 (54.4)
Females 400 (45.6)







ALT level Mean (SD) 95.3 (79.8)
Range 7–668
Reason for visit [no. (%)] Prior HCV diagnosis 346 (39.4)
HCV evaluation 302 (34.4)
Liver disease evaluation 237 (27.0)
Prior HCV therapy [no. (%)] Yes 160 (18.2)
No 718 (81.8)
Clinical diagnosis [no. (%)] Chronic HCV infection 636 (72.4)
Autoimmune hepatitis 20 (2.3)
Alcoholic liver disease 49 (5.6)
Chronic HBV infection 37 (4.2)
Primary biliary cirrhosis 45 (5.1)
Cryptogenic cirrhosis 18 (2.0)
Chronic renal failure 3 (0.3)
Other 106 (12.1)
Liver biopsy performed [no. (%)] Yes 515 (58.6)
No 363 (41.4)
TABLE 2. Number, types, and storage conditions of specimens
Site
No. of specimens
Serum stored at: Plasmaa with:
Total
20 to 80°C (2 to 8°C) EDTA ACD
EU 102 35 0 0 137
VCU 344 0 0 0 344
UM 232 35 35 0 302
UW 160 0 126 27 313
Total 838 70 161 27 1,096
a All plasma specimens were stored between 20 and 80°C.
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However, the test formats differ in the ways in which the amplicons are captured
and detected. In the COBAS test, biotinylated amplicons are captured by mag-
netic particles coated with oligonucleotide probes specific for either HCV or the
IC. HCV OD values were interpreted as follows: 0.15, negative; 0.15 and
1.0, equivocal; and 1.0, positive. An OD value of 0.15 was used as the cutoff
for the IC. Any specimens with OD values of 0.15 for both HCV and IC wells
were considered PI. The differences in the cutoff values between the COBAS and
AMPLICOR HCV tests are due to the differences in the wavelengths of light
used to measure the color development (660 versus 450 nm).
Clinical specimen protocol. Each investigation site collected either serum or
plasma or both from patients who met the study entrance criteria. AMPLICOR
HCV Test v2.0, COBAS AMPLICOR HCV Test v2.0, EIA, and ALT tests were
performed on each specimen. RIBA testing was performed on all EIA-positive
specimens.
Specimens that tested equivocal in either AMPLICOR test were also retested
in duplicate using a second aliquot. Specimens with at least one repeat test result
greater than or equal to the assay cutoff for negative were considered positive for
HCV RNA. Specimens with both duplicate repeat test results less than the assay
cutoff for negative were considered negative for HCV RNA provided that the IC
results for both replicates were valid.
For specimens that were found to be PI in either AMPLICOR test, another
aliquot of the original specimen was processed and amplified in duplicate. HCV
RNA results for these samples were interpreted as described for the equivocal
samples if valid IC OD values were obtained. If no valid IC OD value was
obtained on retesting, the sample remained PI.
The criteria used to interpret the AMPLICOR test results relative to serology
results are shown in Table 3. The AMPLICOR test results obtained in each test
format were evaluated against the serological results independently. APS RT-
PCR analysis was performed on all specimens with false-positive and false-
negative AMPLICOR test results relative to serology results.
Reproducibility study. A reproducibility study was performed to assess the
within-day, within-site, and total reproducibilities of the AMPLICOR and the
COBAS AMPLICOR HCV tests. Qualified testing personnel at three study sites
(EU, UM, and UW) and at Roche Molecular Systems participated in the study.
A commercially available panel of specimens was used (BBI Panel MHW402;
Boston, Mass.). Each plasma panel contained eight tubes consisting of four
negative and four positive samples containing 200, 400, 500, and 50,000 HCV
copies/ml. The panel samples and the kit controls were tested in duplicate on
each day for 4 days at one site (UM) and for 5 days at the other sites. The panel
samples were coded, and the participants were blinded to the expected results.
Data analysis. The parameters use to assess the performance characteristics of
the tests relative to serology were prevalence, sensitivity, and specificity. Four
separate analyses were performed using these three parameters by study site and
across all sites. Agreement with EIA results were assessed separately in the
diagnosis, previously treated, and posttransplant patient groups, and correlated
with the ALT levels in liver histology reports.
Reproducibility was assessed by computing the proportion of true positives
and true negatives, separately, by run number and concentration of HCV RNA
copies/ml in each sample by site. Sites were combined, and the same proportions
were calculated across sites by concentration of HCV RNA.
Statistical software SAS version 6.12 was used to analyze the data and compute
the 95% confidence intervals. All 95% confidence intervals are exact intervals
calculated using cumulative binomial methods.
RESULTS
The clinical performance of the AMPLICOR HCV Test v2.0
versus that of serology across all sites and patient groups is
shown in Table 4. Overall, 905 serum and 188 plasma speci-
mens were tested at the four sites with the AMPLICOR Test.
There were three unresolved PI serum specimens and one
unresolved equivocal serum specimen that were excluded from
the data analysis. Therefore, valid test results were available
for 901 (99.6%) serum specimens. Valid AMPLICOR results
were available for all of the plasma samples tested. The prev-
alence of HCV antibody was 69.4% in the serum group and
76.6% in the plasma group. The AMPLICOR test with serum
samples had a sensitivity of 93.1% and a specificity of 97%
compared to serology. The test performance characteristics
with plasma samples were similar (sensitivity, 90.6%; specific-
ity, 93.1%).
There were no substantive differences in test performance
characteristics between the study sites (Table 4). In addition,
there were no notable differences in clinical performance be-
tween serum samples stored at 2 to 8°C versus 20 to 80°C
and EDTA-plasma versus ACD-plasma (data not shown).
There were 46 serum samples classified as false negative
when compared with serology. Forty-five samples were re-
tested, and 44 (97.8%) were found to be negative for HCV
RNA in all three APS RT-PCR assays. All of the 15 false-
negative plasma specimens were negative for HCV RNA in all
of the APS RT-PCR assays. False-positive AMPLICOR results
occurred with seven serum and two plasma specimens. Four of
TABLE 3. Interpretation of AMPLICOR and COBAS
AMPLICOR HCV test, v2.0 results compared
to HCV serology results
AMPLICOR
result EIA result RIBA result
AMPLICOR
interpretation
Positive Positive Positive True positive
Positive Positive Indeterminate True positive
Positive Positive Negative False positive
Positive Negative Not done False positive
Negative Negative Not done True negative
Negative Positive Positive False negative
Negative Positive Indeterminate False negative
Negative Positive Negative True negative








TP TN FP FN % Sensitivity (95% CI)b % Specificity (95% CI)
EU Serum 136 113 13 0 10 83.1 91.9 (85.6–96.0) 100 (73.5–100)
VCU Serum 343 212 117 3 11 61.8 95.1 (91.3–97.5) 97.5 (92.9–99.5)
UM Serum 266 173 77 3 13 65.0 93.0 (88.3–96.2) 97.5 (89.4–99.2)
UM Plasma 35 25 8 0 2 71.4 92.6 (75.7–99.1) 100 (63.1–100)
UW Serum 156 124 19 1 12 79.5 91.2 (85.1–95.4) 95.0 (75.1–99.9)
UW Plasma 153 119 19 2 13 77.8 90.2 (83.7–94.7) 95.2 (69.6–98.8)
All Serum 901 622 226 7 46 69.4 93.1 (90.9–94.9) 97.0 (93.9–98.8)
Plasma 188 144 27 2 15 76.6 90.6 (84.9–94.6) 93.1 (77.2–99.2)
a TP, true positive; TN, true negative; FP, false positive; FN, false negative in comparison with HCV serology results as defined in Table 3.
b CI, confidence interval.
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the serum and one of the plasma specimens were positive for
HCV RNA in at least one of the APS RT-PCR assays. Thus, of
the 69 samples classified as either false negative or false pos-
itive relative to serology, the AMPLICOR test provided the
correct result relative to the specimen containing HCV RNA
in 64 (92.7%) specimens.
Only five (0.6%) serum and no plasma specimens had OD
values that were in the equivocal range (0.3 to 1) of the AM-
PLICOR assay. Four of the five sera were retested in duplicate.
Upon retesting, two resolved as positive and two resolved as a
negative.
Ten (1.1%) serum specimens were found to be PI on initial
testing. Eight of these were retested and only one remained PI.
Of the seven specimens that gave valid IC results on retesting,
six were HCV RNA negative and one was HCV RNA positive.
Four (2.1%) plasma samples were found to be PI on initial
testing. All gave valid IC results on retesting (three negative
and one positive for HCV RNA).
The clinical performance of the COBAS test versus that of
serology across all sites and patient groups is shown in Table 5.
Overall, 908 serum and 188 plasma specimens were tested at
the four sites. All but 12 (1.3%) serum specimens gave valid
COBAS test results, including eight unresolved PI and four
unresolved equivocal specimens. These specimens were ex-
cluded from the data analysis. Valid COBAS test results were
available for all plasma specimens. The prevalence of HCV
antibody was 69.4% in the serum group and 76.6% in the
plasma group. The COBAS test with serum specimens had a
sensitivity of 93.1% and a specificity of 97.8% compared to
serology. The test performance characteristics with plasma
specimens were similar (sensitivity, 90.6%; specificity, 96.6%).
There were no substantive differences in test performance
characteristics between the study sites (Table 5). In addition,
no notable differences in clinical performance between serum
specimens stored at 2 to 8°C versus 20 to 80°C and between
EDTA-plasma versus ACD-plasma were found (data not
shown).
There were 46 serum and 15 plasma specimens that were
HCV antibody positive but negative for HCV RNA in the
COBAS test. All of these samples were also negative for HCV
RNA in all three alternative primer pair RT-PCR assays.
False-positive COBAS test results occurred with five serum
and one plasma specimens. Four of the sera and the single
plasma specimen were positive in at least one of the APS
RT-PCR assays. Thus, of the 67 samples with discrepant anti-
body and RNA results, the COBAS test provided the correct
result relative to the sample containing HCV RNA in 66
(98.5%) samples.
Only 12 (1.3%) sera and one (0.5%) plasma specimen had
OD values that were in the equivocal range in the COBAS test.
Eight of the 12 sera and the single plasma specimen were
retested in duplicate. Upon retesting, one serum and the
plasma specimen resolved as positive, and seven serum speci-
mens resolved as negative. The seven resolved HCV RNA-
negative sera were also negative in all three of the APS RT-
PCR assays.
Twenty-seven (3%) serum and no plasma specimens were
found to be PI on initial testing with the COBAS test. Twenty-
four of the sera were retested, and only five remained PI. Of
the 19 specimens that gave valid IC results upon retesting, 3
were positive and 16 were negative for HCV RNA.
Both AMPLICOR and COBAS test results were available
for 1,076 specimens. The results were concordant for 1,071
(99.5%) specimens. The discordant test results for the five








TP TN FP FN % Sensitivity (95% CI)b % Specificity (95% CI)
EU Serum 137 114 13 0 10 83.2 91.9 (85.7–96.1) 100 (75.3–100)
VCU Serum 341 213 114 3 11 62.5 95.1 (91.4–97.5) 97.4 (92.7–99.5)
UM Serum 265 173 77 2 13 65.3 93.0 (88.3–96.2) 97.5 (91.2–99.7)
UM Plasma 35 25 8 0 2 71.4 92.6 (75.7–99.1) 100 (63.1–100)
UW Serum 153 122 19 0 12 79.7 91.0 (84.9–95.3) 100 (82.4–100)
UW Plasma 153 119 20 1 13 77.8 90.2 (83.7–94.7) 95.2 (76.2–99.9)
All Serum 896 622 223 5 46 69.4 93.1 (90.9–94.9) 97.8 (95.0–99.3)
Plasma 188 144 28 1 15 76.6 90.6 (84.9–94.6) 96.6 (82.2–99.9)
a TP, true positive; TN, true negative; FP, false positive; FN, false negative in comparison with HCV serology results as defined in Table 3.
b CI, confidence interval.
TABLE 6. Summary of results for specimens that were discordant in the AMPLICOR HCV v2.0 tests
Site Specimen no. Specimen type AMPLICOR COBAS AMPLICOR EIA RIBA APS RT-PCR
VCU 254 Serum (frozen) Negative Positive Positive Positive Positivea
UM 62 Serum (frozen) Positive Negative Positive Positive Negative
UM 209 Serum (frozen) Positive Negative Negative NDb Negative
UW 35 Serum (frozen) Positive Negative Negative ND Positivec
UW 1157 Plasma (ACD) Positive Negative Negative ND Negative
a Positive in 5 UTR, core, and E1 APS RT-PCR.
b ND, not determined.
c Positive only in the E1 APS RT-PCR.
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remaining specimens are shown in Table 6. APS RT-PCR
analysis confirmed the COBAS test result in four of five cases.
We also compared the serological and COBAS test results
separately in the diagnosis, previously treated, and posttrans-
plant patient groups. Only serum specimens and patients with
liver biopsy results were included in this analysis. In each
patient group we assessed the agreement between the EIA and
COBAS test results by disease state as determined by ALT
levels and liver biopsy results.
The overall agreement between EIA and COBAS test re-
sults was 98.6% for the 294 patients included in the diagnosis
group (Table 7). Among patients with elevated ALT levels and
hepatitis as determined by histology, HCV RNA was detected
in 164 of 166 (98.8%) EIA-positive and in none of the 16
EIA-negative patients. HCV RNA was detected in all of the 59
EIA-positive and none of the 9 EIA-negative patients with
normal ALT levels and hepatitis. Complete concordance be-
tween the EIA and COBAS test results was found in the 20
patients with elevated ALT and no hepatitis. The single EIA-
positive patient in this category also had HCV RNA detected
in serum. In patients with normal ALT levels and no hepatitis,
there was 91.7% agreement between the EIA and COBAS test
results. HCV RNA was detected in one of two (50%) EIA-
positive patients and in one of 22 (4.5%) EIA-negative patients
in this category.
The overall agreement between EIA and COBAS test re-
sults was 92.5% for the 120 patients included in the previously
treated group (Table 8). All of the patients in this group were
EIA positive, and all but one had hepatitis. Among patients
with hepatitis, HCV RNA was detected in 89 of 91 (97.8%)
patients with elevated ALT levels and in 22 of 28 patients
(78.6%) with normal ALT levels. No HCV RNA was detected
in the remaining patient in this group, who had an elevated
ALT level but no evidence of hepatitis on biopsy.
The overall agreement between EIA and COBAS test re-
sults was 87.5% for the 16 patients who had undergone liver
transplantation (Table 9). Fourteen patients were EIA posi-
tive. HCV RNA was not detected in two EIA-positive patients,
one with normal ALT levels and hepatitis, and the other with
normal ALT levels and no hepatitis.
The AMPLICOR test results in the three patient groups
were very similar to those obtained with the COBAS test (data
not shown). There were too few plasma specimens to make
meaningful comparisons with the other markers of liver dis-
ease in the different patient groups.
During the study there were 101 runs of the AMPLICOR
test, of which 93 (92%) provided valid results. Of the eight
failed runs, five (62.5%) were due to positive controls being
low, one (12.5%) was due to both a positive and negative
control out of range, and two (25%) runs were repeated be-
cause the samples used in the run were past the storage sta-
bility date.
TABLE 7. Performance of the COBAS AMPLICOR HCV Test
v2.0 compared to serological, biochemical, and histological



















EIA/RIBA 162 2 98.8 (95.7–99.8)
EIA/RIBA IND 2 0 100.0 (15.8–100.0)
EIA/RIBA 0 0
EIA 0 16 100.0 (79.4–100.0)
Normal ALT
and hepatitis
EIA/RIBA 58 0 100.0 (93.8–100.0)
EIA/RIBA IND 1 0 100.0 (2.5–100.0)
EIA/RIBA 0 0
EIA 0 9 100.0 (66.4–100.0)
Elevated ALT and
no hepatitis
EIA/RIBA 1 0 100.0 (2.5–100.0)
EIA/RIBA IND 0 0
EIA/RIBA 0 0
EIA 0 19 100.0 (82.4–100.0)
Normal ALT and
no hepatitis
EIA/RIBA 0 1 0.0 (0.0–97.5)
EIA/RIBA IND 1 0 100.0 (2.5–100.0)
EIA/RIBA 0 0
EIA 1 21 95.5 (77.2–99.9)
a CI, confidence interval.
TABLE 8. Performance of the COBAS AMPLICOR HCV Test
v2.0 compared to serological, biochemical, and histological



















EIA/RIBA 85 2 97.7 (91.9–99.7)





EIA/RIBA 22 5 81.5 (61.9–93.7)





EIA/RIBA 0 1 0.0 (0.0–97.5)
EIA/RIBA IND 0 0
EIA/RIBA 0 0
EIA 0 0
a There were no cases showing normal ALT levels and no hepatitis in this
patient group.
b CI, confidence interval.
TABLE 9. Performance of the COBAS AMPLICOR HCV Test
v2.0 compared to serological, biochemical, and histological



















EIA/RIBA 9 0 100.0 (66.3–100.0)





EIA/RIBA 2 0 100.0 (15.8–100.0)





EIA/RIBA 0 1 0.0 (0.0–97.5)
EIA/RIBA IND 0 0
EIA/RIBA 0 0
EIA 0 2 100.0 (15.8–100.0)
a There were no cases showing elevated ALT levels and no hepatitis in this
patient group.
b CI, confidence interval.
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There were 394 runs of the COBAS HCV attempted during
the study, of which 357 (91%) provided valid results. Of the 37
runs of study specimens which failed, 6 (16%) were due to
positive controls being low, 5 (14%) were due to the negative
control out of range, and 3 (8%) were due to both a positive
and negative control out of range. Also, 18 (48%) runs were
repeated because the samples used in the run were past the
storage stability date. Finally, mechanical problems with the
analyzer resulted in five (14%) failed runs.
The reproducibility study results across all sites for the AM-
PLICOR and the COBAS tests are summarized in Table 10.
Examination of the AMPLICOR test results shows that of 153
negative panel members tested only 1 gave a positive result
(99.3% correct results). Of the 151 positive panel members
tested, only 1, at a concentration of 500 copies/ml, was falsely
negative (99.3% correct results). One negative panel member
was PI and dropped from the analysis.
Examination of the COBAS test results shows that of 171
negative panel members tested, all samples were correctly
identified as negative (100% correct results). Of the 171 pos-
itive panel members tested, only 1 panel member, at a concen-
tration of 500 copies/ml, was falsely negative (99.4% correct
results). Four panel members were PI and not included in the
data analysis.
Reproducibility within runs and within sites was also 99%
for both tests (data not shown). All sites were able to detect all
the panel members with the lowest concentration of HCV
RNA (200 copies/ml). Therefore, the analytical sensitivity for
both tests, as assessed with this panel, was 200 copies/ml.
DISCUSSION
Our study is the first multicenter clinical evaluation of the
AMPLICOR and COBAS AMPLICOR HCV v2.0 tests. The
patients in this study were enrolled at four liver disease clinics
in the United States and had a high prevalence of HCV infec-
tion. The two tests were evaluated independently using sam-
ples obtained from the same patients and were found to have
almost identical test performance characteristics when serol-
ogy was used as the diagnostic “gold standard”. The results for
the AMPLICOR and COBAS tests were also found to be
highly concordant with each other.
We found that approximately 7% of HCV antibody-positive
specimens had no detectable RNA by the AMPLICOR meth-
ods. These were scored as false-negative AMPLICOR results.
However, all but one specimen also had no detectable HCV
RNA by the APS RT-PCR used in the discrepant sample
analysis. We conclude that the RNA-negative patients were
not viremic at the time the samples were drawn due to either
intermittent viremia or viral clearance. Our study could not
distinguish between these two possibilities since patients were
sampled at only one time point.
We demonstrated that four test sites could consistently de-
tect samples containing as few as 200 HCV RNA copies/ml.
The manufacturer has shown that the second-generation tests
can detect 100% of samples containing as little as 50 IU/ml
(approximately 100 copies/ml) (13). Although the fluctuations
in viral load that occur in patients chronically infected with
HCV are not well defined, it is rare to find patients with viral
loads of 104 copies/ml in the absence of therapy (8, 12, 14, 15,
17–20). Thus, it appears that the analytical sensitivity of the
AMPLICOR tests is at least 100-fold lower than the lowest
value likely to be encountered in patients being evaluated for
HCV infection prior to therapy. However, enhanced sensitivity
may be required for other applications such as detection of
HCV RNA in blood donor plasma pools (9) or assessment of
virologic response at the end of treatment (16). Recently, a
transcription-mediated amplification assay (Gen-Probe, San
Diego, Calif.) with a sensitivity of 10 to 50 copies/ml was shown
to detect HCV RNA in 36% of patients who were classified as
virologic end-of-treatment responders with subsequent relapse
according to the results of the AMPLICOR HCV Test v2.0
(16).
The inclusion of an IC that is extracted and amplified simul-
taneously with the clinical specimen increases the level of con-
fidence in negative RT-PCR results. However, only 1.1 and 3%
of specimens tested with AMPLICOR and COBAS tests, re-
spectively, had invalid IC results. Most (75%) of the IC failures
were probably due to inefficient nucleic acid extraction rather
than to the presence of inhibitors in the specimens because the
problem resolved upon retesting. Recovery of the RNA pellet
is the most technically demanding step in these procedures.
Although no standards exist for an acceptable number of false-
negative tests, the low rates reported here call into question
the need for an IC. The inclusion of an IC adds substantial
expense to the tests and, in our experience, was of limited
value. A more cost-effective strategy in a diagnostic setting
would be to omit the IC and simply retest all patients with a
negative HCV RNA test and high index of clinical suspicion of
active infection.
Both the AMPLICOR and COBAS AMPLICOR tests were
very specific relative to serology (97%). Overall, HCV RNA
was detected by APS RT-PCR analysis in five of eight (62%)
clinical specimens with false-positive test results. The reason
TABLE 10. Reproducibility of the AMPLICOR and COBAS AMPLICOR HCV v2.0 testsa





No. of specimens tested % Correct result 95% CIb No. of specimens tested % Correct result 95% CI
0 Negative 153 99.3 96.4–99.9 171 100 97.9–100
200 Positive 38 100 90.1–100 43 100 91.8–100
300 Positive 38 100 90.8–100 42 100 91.6–100
500 Positive 38 97.4 86.2–99.9 43 97.7 87.1–99.9
50,000 Positive 38 100 90.8–100 43 100 91.8–100
a Pooled data from four test sites (EU, UM, UW, and Roche Molecular Systems). Results for five PI panel members were excluded from the data analysis (one in
AMPLICOR and four in COBAS AMPLICOR).
b CI, confidence interval.
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for the negative antibody test results for the patients with
confirmed viremia was not clear. Three of these patients were
previously documented to be HCV antibody positive and
chronically infected with HCV. Circulating immune complexes
or a general state of immunosuppression may have accounted
for the loss of a detectable HCV antibody response in these
patients. The remaining two patients had no identified risk
factors for HCV infection and other liver diseases. Either these
patients were truly infected with HCV but had not serocon-
verted or, more likely, their specimens were mislabeled or
contaminated with HCV during processing.
The AMPLICOR and COBAS tests have several features
that may account for the low false-positive rates observed in
this study. Uracil-N-glycosylase and dUTP are incorporated
into the reaction mixtures to avoid false positives due to prod-
uct carryover from one sample to another (14). The establish-
ment of equivocal zones for the test results and an algorithm
for retesting equivocal samples also reduced the number of
false-positive results. However, these features cannot prevent
false-positive tests that may result from cross contamination of
specimens with target nucleic acid during processing.
We also evaluated the clinical performances of the AMPLI-
COR and COBAS tests, independently, for patients presenting
for diagnosis or evaluation of liver disease, for patients who
had received antiviral therapy for hepatitis C more than 6
months prior to enrollment, and for patients who had under-
gone liver transplantation. Overall, we found a high concor-
dance between the RNA and serological test results in all three
patient groups, which was independent of disease state. The
results were concordant in 98.6, 92.5, and 87.5% of patients in
the diagnosis, previously treated, and posttransplant groups,
respectively. The lower overall concordance between the RNA
and serological test results in the previously treated and post-
transplant groups probably is the result of the clinical inter-
ventions rather than any problems with the RNA tests in these
groups of patients.
Serious concerns about HCV RNA testing have been raised
by the poor performance of laboratories that participated in an
HCV RNA proficiency-testing program (4). In this perfor-
mance survey of 86 laboratories performing HCV RNA detec-
tion, only 16% of the laboratories performed faultlessly. Sur-
vey participants using the earlier versions of the AMPLICOR
tests tended to have a sufficient quality score more often than
those labs using in-house-developed methods (64 versus 45%;
P  0.11). We found both the AMPLICOR and COBAS v.2.0
tests to be highly reproducible at four different test sites. All
sites reported 99% correct results for a total of 324 negative
and 323 positive panel members. In addition, there were no
substantive differences between the sites in the test perfor-
mance characteristics with clinical specimens.
Both the manual and automated formats for the HCV RNA
tests were highly reliable, but, surprisingly, the COBAS AM-
PLICOR analyzer did not improve the reliability or reproduc-
ibility of the HCV RNA test. However, the labor savings in
laboratories doing large numbers of tests may offset the ex-
pense of the instrument.
Both HCV RNA tests could be performed using serum,
EDTA-plasma, or ACD-plasma with no substantive differ-
ences in test performance characteristics. We also found no
differences in test performance characteristics attributable to
the temperatures at which the specimens were stored prior to
testing (refrigerated versus frozen).
Our data support the current recommendation that a posi-
tive HCV EIA test should be confirmed by a qualitative test for
HCV RNA rather than by RIBA in patients with a high pretest
probability of infection (6, 7). The RIBA was negative in only
1 (0.1%) and was indeterminate in 34 (4.2%) EIA-positive
patients. The AMPLICOR HCV tests detected the presence of
HCV RNA in 62% of the RIBA-indeterminate specimens and,
thus, confirmed that these patients were actively infected with
HCV. HCV RNA tests can distinguish active from resolved
infections; however, a single negative RNA test is not conclu-
sive evidence of resolved infection because viremia in chroni-
cally infected individuals may be intermittent (8, 11). In our
population only 7% of EIA-positive patients were RNA neg-
ative and would have required additional testing to establish
whether their infection was active or resolved.
In conclusion, both the AMPLICOR and COBAS AMPLI-
COR v2.0 HCV tests demonstrated good overall agreement
with serology results and other markers of liver disease and
had excellent reproducibility across study sites and specimen
types. These tests can reliably detect the presence of HCV
RNA, as evidence of active infection, in patients with clinical
or biochemical evidence of liver disease. The performance
characteristics of these tests in low-prevalence patient popula-
tions or as a means to assess end-of-treatment responses are
yet to be established.
ACKNOWLEDGMENTS
Funding for this work was provided by Roche Molecular Systems,
Inc., Pleasanton, Calif.
We thank Kelsey Lowitz-Singer, Allison Murray, Karen Gutekunst,
and David Thomas of Roche Molecular Systems for their help with
logistics and data analysis.
REFERENCES
1. Bukh, J., R. H. Purcell, and R. H. Miller. 1992. Importance of primer
selection for the detection of hepatitis C virus RNA with the polymerase
chain reaction assay. Proc. Natl. Acad. Sci. USA 89:187–191.
2. Bukh, J., R. H. Purcell, and R. H. Miller. 1994. Sequence analysis of the core
gene of 14 hepatitis C virus genotypes. Proc. Natl. Acad. Sci. USA 91:8239–
8243.
3. Centers for Disease Control and Prevention. 1998. Recommendations for
prevention and control of hepatitis C virus (HCV) infection and HCV-
related chronic disease. Morb. Mortal. Wkly. Rep. 47:1–39.
4. Damen, M., H. T. M. Cuypers, H. L. Zaaijer, H. W. Reesink, W. P. Schaas-
berg, W. H. Gerlich, H. G. M. Niesters, and P. N. Lelie. 1996. International
collaborative study on the second EUROHEP HCV-RNA reference panel.
J. Virol. Methods 58:175–185.
5. Doglio, A., C. Laffont, F. X. Caroli-Bosc, P. Rochet, and J.-C. Lefebvre. 1999.
Second generation of the automated Cobas Amplicor HCV assay improves
sensitivity of hepatitis C virus RNA detection and yields results that are more
clinically relevant. J. Clin. Microbiol. 37:1567–1569.
6. DuFour, D. R., J. A. Lott, F. S. Nolte, D. Gretch, R. S. Koff, and L. B. Seeff.
2000. Diagnosis and monitoring of hepatic injury. II. Recommendations for
use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem.
46:2050–2068.
7. European Association for the Study of the Liver. 1999. EASL International
Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, Con-
sensus statement. J. Hepatol. 30:956–961.
8. Fanning, L., E. Kenny-Walsh, J. Levis, K. R. Choudhury, B. Cannon, M.
Sheehan, M. Whelton, and F. Shanahan. 2000. Natural fluctuations of hep-
atitis C viral load in the homogeneous patient population: a prospective
study. Hepatology 31:225–229.
9. Gallarda, J. L., and E. Dragon. 2000. Blood screening by nucleic acid am-
plification technology: current issues, future challenges. Mol. Diagn. 5:11–22.
10. Gretch, D., J. J. Wilson, R. L. Carithers, Jr., C. dela Rosa, J. H. Han, and L.
Corey. 1993. Detection of hepatitis C virus RNA: comparison of one-stage
polymerase chain reaction (PCR) with nested-set PCR. J. Clin. Microbiol.
31:289–291.
VOL. 39, 2001 CLINICAL EVALUATION OF HCV RNA TESTS 4011
11. Gretch, D., W. Lee, and L. Corey. 1992. Use of aminotransferase, hepatitis C
antibody, and hepatitis C polymerase chain reaction RNA assays to establish
the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory.
J. Clin. Microbiol. 30:2145–2149.
12. Hagiwara, H., N. Hayashi, E. Mita, M. Naito, A. Kasahara, and H.
Fusamoto. 1993. Quantitation of hepatitis C virus RNA in serum of asymp-
tomatic blood donors and patients with type C chronic liver disease. Hepa-
tology 17:545–550.
13. Lee, S. C., A. Anthony, J. Leibox, J. Q. Yang, S. Soviero, K. Gutekunst, and
M. Rosensraus. 2000. Improved version 2.0 qualitative and quantitative
AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA:
calibration to international units, enhanced genotype reactivity, and perfor-
mance characteristics. J. Clin. Microbiol. 38:4171–4170.
14. Longo, M. C., M. S. Berninger, and J. L. Hartley. 1990. Use of uracil DNA
glycosylase to control carry-over contamination in polymerase chain reac-
tions. Gene 93:125–128.
15. National Institutes of Health. 1997. National Institutes of Health Consensus
Development Conference Panel Statement: management of hepatitis C.
Hepatology 26(3 Suppl. 1):2S–10S.
16. Sarrazin, C., G. Teuber, R. Kokka, H. Rabenau, and S. Zeuzem. 2000.
Detection of residual hepatitis C virus RNA by transcription-mediated am-
plification of patients with complete virologic response according to poly-
merase chain reaction-based assays. Hepatology 32:818–823.
17. Sullivan, D. G., J. J. Wilson, R. L. Carither, J. D. Perkins, and D. Gretch.
1998. Multigene tracking of hepatitis C virus quasispecies after liver trans-
plantation: correlation of genetic diversification in the envelope region with
asymptomatic or mild disease patterns. J. Virol. 72:10036–10043.
18. Trabaud, M. D., F. Bailly, S. N. Si-Ahmed, P. Chevallier, M. Sepetjan, G.
Colucci, and C. Trepo. 1997. Comparison of HCV RNA assays for the
detection and quantification of hepatitis C virus RNA levels in serum of
patients with chronic hepatitis C treated with interferon. J. Med. Virol.
52:105–112.
19. Villano, S. A., D. Vlahov, K. E. Nelson, S. Cohen, and D. L. Thomas. 1999.
Persistence of viremia and the importance of long-term follow-up after acute
hepatitis C infection. Hepatology 29:908–914.
20. Zeuzem, S., J. H. Lee, A. Franke, B. Ruster, O. Prummer, G. Herrmann, and
W. K. Roth. 1998. Quantification of the initial decline of serum hepatitis C
virus RNA and response to interferon alfa. Hepatology 27:1149–1156.
4012 NOLTE ET AL. J. CLIN. MICROBIOL.
